12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Elelyso taliglucerase alfa regulatory update

Pfizer and partner Protalix said the European Commission refused to approve an MAA for Orphan Drug Elelyso taliglucerase alfa to treat Type I Gaucher's disease. In June, EMA's CHMP recommended against approval of the MAA. The committee said Elelyso has a positive benefit-risk profile but approval of the product...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >